BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. Source
No articles found.
Alzamend Neuroâ˘, Inc. (âAlzamendâ˘â) is a biotechnology company dedicated t...
Alzamend Neuroâ˘, Inc. (âAlzamendâ˘â) is ...
For more than 40 years, IntriCon has been meeting the rising demand for smaller, p...
For more than 40 years, IntriCon has been meeti...
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...
GENFIT is a late-stage biopharmaceutical compan...
Osmotica Pharmaceuticals plc is a fully-integrated biopharmaceutical company focus...
Osmotica Pharmaceuticals plc is a fully-integra...
We are an international biotechnology company that is focused in the field of rege...
We are an international biotechnology company t...
We have used biochemical, molecular & cell biology and in vivo models to screen, i...
We have used biochemical, molecular & cell biol...
Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-onco...
Leap Therapeutics (NASDAQ: LPTX) is focused on ...
Join the National Investor Network and get the latest information with your interests in mind.